News & Events
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Crinetics management will participate in a fireside chat on November 30, 2022 at the 5th Annual Evercore ISI HealthCONx Conference
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on third quarter 2022 clinical progress including an expectation of topline data from PATHFNDR-1 in 2023
READ MORECrinetics Announces November 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces November 2022 inducement grants: the stock options were granted as inducements material to four employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MOREEnrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
Enrollment is complete in the placebo-controlled Phase 3 PATHFNDR-1 study evaluating safety and efficacy of once-daily oral paltusotine in acromegaly patients
READ MORECrinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces October 2022 inducement grants: the stock options were granted as inducements material to 11 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MOREInnovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
The UK Medicines and Healthcare products Regulatory Agency has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism.
READ MORECrinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
Crinetics appoints Dana Pizzuti, M. D. , a 30-year pharmaceutical industry veteran, to the newly created role of chief development officer
READ MORECrinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
